162 related articles for article (PubMed ID: 28356850)
1. Influence of Promoter Polymorphisms of the TNF-α (-308G/A) and IL-6 (-174G/C) Genes on Therapeutic Response to Etanercept in Rheumatoid Arthritis.
Jančić I; Šefik-Bukilica M; Živojinović S; Damjanov N; Spasovski V; Kotur N; Klaassen K; Pavlović S; Bufan B; Arsenović-Ranin N
J Med Biochem; 2015 Oct; 34(4):414-421. PubMed ID: 28356850
[TBL] [Abstract][Full Text] [Related]
2. -174G/C interleukin-6 gene promoter polymorphism predicts therapeutic response to etanercept in rheumatoid arthritis.
Jančić I; Arsenović-Ranin N; Sefik-Bukilica M; Zivojinović S; Damjanov N; Spasovski V; Srzentić S; Stanković B; Pavlović S
Rheumatol Int; 2013 Jun; 33(6):1481-6. PubMed ID: 23233117
[TBL] [Abstract][Full Text] [Related]
3. TNF-alpha gene polymorphisms can help to predict response to etanercept in psoriatic patients.
De Simone C; Farina M; Maiorino A; Fanali C; Perino F; Flamini A; Caldarola G; Sgambato A
J Eur Acad Dermatol Venereol; 2015 Sep; 29(9):1786-90. PubMed ID: 25726968
[TBL] [Abstract][Full Text] [Related]
4. Association of tumor necrosis factor-alpha promoter region gene polymorphism at positions -308G/A, -857C/T, and -863C/A with etanercept response in Iraqi rheumatoid arthritis patients.
Mohammed S; Zalzala M; Gorial F
Arch Rheumatol; 2022 Dec; 37(4):613-625. PubMed ID: 36879565
[TBL] [Abstract][Full Text] [Related]
5. Interleukin-6 promoter haplotypes are associated with etanercept response in patients with rheumatoid arthritis.
Schotte H; Schmidt H; Gaubitz M; Drynda S; Kekow J; Willeke P; Schlüter B
Clin Rheumatol; 2015 Dec; 34(12):2021-8. PubMed ID: 26526676
[TBL] [Abstract][Full Text] [Related]
6. Etanercept reduces matrix metalloproteinase-9 level in children with polyarticular juvenile idiopathic arthritis and TNF-alpha-308GG genotype.
Basic J; Pavlovic D; Jevtovic-Stoimenov T; Vojinovic J; Susic G; Stojanovic I; Kocic G; Milosevic V; Cvetkovic T; Marinkovic M; Veljkovic A
J Physiol Biochem; 2010 Jun; 66(2):173-80. PubMed ID: 20596903
[TBL] [Abstract][Full Text] [Related]
7. Promoter polymorphism of
Kamdee K; Panadsako N; Mueangson O; Nuinoon M; Janwan P; Poonsawat W; Pongpanitanont P; Kitkumthorn N; Thongsroy J; Chunglok W
Biomed Rep; 2021 Sep; 15(3):78. PubMed ID: 34405050
[TBL] [Abstract][Full Text] [Related]
8. Tumor Necrosis Factor Alpha -308G/A Gene Polymorphisms Combined with Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratio Predicts the Efficacy and Safety of Anti-TNF-α Therapy in Patients with Ankylosing Spondylitis, Rheumatoid Arthritis, and Psoriasis Arthritis.
Wang Z; Kong L; Zhang H; Sun F; Guo Z; Zhang R; Dou Y
Front Pharmacol; 2021; 12():811719. PubMed ID: 35126146
[No Abstract] [Full Text] [Related]
9. The -174G/C and -572G/C interleukin 6 promoter gene polymorphisms in mexican patients with rheumatoid arthritis: a case-control study.
Zavaleta-Muñiz SA; Martín-Márquez BT; Gonzalez-Lopez L; Gonzalez-Montoya NG; Díaz-Toscano ML; Ponce-Guarneros JM; Ruiz-Padilla AJ; Vázquez-Del Mercado M; Maldonado-González M; Fafutis-Morris M; Flores-Martínez SE; Martínez-García EA; Gamez-Nava JI
Clin Dev Immunol; 2013; 2013():959084. PubMed ID: 24223608
[TBL] [Abstract][Full Text] [Related]
10. Confirmation of -174G/C interleukin-6 gene promoter polymorphism as a genetic marker predicting antitumor necrosis factor treatment outcome.
Dávila-Fajardo CL; Márquez A; Pascual-Salcedo D; Moreno Ramos MJ; García-Portales R; Magro C; Alegre-Sancho JJ; Balsa A; Cabeza-Barrera J; Raya E; Martín J
Pharmacogenet Genomics; 2014 Jan; 24(1):1-5. PubMed ID: 24253594
[TBL] [Abstract][Full Text] [Related]
11. Effects of polymorphisms in TRAILR1 and TNFR1A on the response to anti-TNF therapies in patients with rheumatoid and psoriatic arthritis.
Morales-Lara MJ; Cañete JD; Torres-Moreno D; Hernández MV; Pedrero F; Celis R; García-Simón MS; Conesa-Zamora P
Joint Bone Spine; 2012 Dec; 79(6):591-6. PubMed ID: 22480748
[TBL] [Abstract][Full Text] [Related]
12. Tumour necrosis factor alpha promoter polymorphisms and etanercept therapy in juvenile idiopathic arthritis.
Schmeling H; Horneff G
Rheumatol Int; 2007 Feb; 27(4):383-6. PubMed ID: 16951943
[TBL] [Abstract][Full Text] [Related]
13. Association of the tumour necrosis factor-308 variant with differential response to anti-TNF agents in the treatment of rheumatoid arthritis.
Maxwell JR; Potter C; Hyrich KL; ; Barton A; Worthington J; Isaacs JD; Morgan AW; Wilson AG
Hum Mol Genet; 2008 Nov; 17(22):3532-8. PubMed ID: 18713756
[TBL] [Abstract][Full Text] [Related]
14. Assessment of the
Amr K; El-Awady R; Raslan H
Open Access Maced J Med Sci; 2016 Dec; 4(4):574-577. PubMed ID: 28028393
[TBL] [Abstract][Full Text] [Related]
15. Transforming growth factor β 869C/T and interleukin 6 -174G/C polymorphisms relate to the severity and progression of bone-erosive damage detected by ultrasound in rheumatoid arthritis.
Ceccarelli F; Perricone C; Fabris M; Alessandri C; Iagnocco A; Fabro C; Pontarini E; De Vita S; Valesini G
Arthritis Res Ther; 2011 Jul; 13(4):R111. PubMed ID: 21740541
[TBL] [Abstract][Full Text] [Related]
16. Killer immunoglobulin-like receptor and human leukocyte antigen-C genotypes in rheumatoid arthritis primary responders and non-responders to anti-TNF-α therapy.
McGeough CM; Berrar D; Wright G; Mathews C; Gilmore P; Cunningham RT; Bjourson AJ
Rheumatol Int; 2012 Jun; 32(6):1647-53. PubMed ID: 21373785
[TBL] [Abstract][Full Text] [Related]
17. Cytokine gene polymorphisms in the susceptibility to acute coronary syndrome.
Babu BM; Reddy BP; Priya VH; Munshi A; Rani HS; Latha GS; Rao VD; Jyothy A
Genet Test Mol Biomarkers; 2012 May; 16(5):359-65. PubMed ID: 22372709
[TBL] [Abstract][Full Text] [Related]
18. Effects of the IL6 -174G>C promoter polymorphism and IL-6 serum levels on the progression of cutaneous malignant melanoma.
Vlaykova T; Kurzawski M; Tacheva T; Dimov D; Anastasov A; Vlaykova D; Miteva A; O'donoghue N; Drozdzik M
Oncol Lett; 2020 Aug; 20(2):1781-1791. PubMed ID: 32724421
[TBL] [Abstract][Full Text] [Related]
19. Associations between inflammatory gene polymorphisms (TNF-α 308G/A, TNF-α 238G/A, TNF-β 252A/G, TGF-β1 29T/C, IL-6 174G/C and IL-10 1082A/G) and susceptibility to osteosarcoma: a meta-analysis and literature review.
Jiang Y; Wang X; Cheng Y; Peng J; Xiao J; Tang D; Yi Y
Oncotarget; 2017 Nov; 8(57):97571-97583. PubMed ID: 29228633
[TBL] [Abstract][Full Text] [Related]
20. -174G/C IL-6 gene promoter polymorphism predicts therapeutic response to TNF-α blockers.
Di Renzo L; Bianchi A; Saraceno R; Calabrese V; Cornelius C; Iacopino L; Chimenti S; De Lorenzo A
Pharmacogenet Genomics; 2012 Feb; 22(2):134-42. PubMed ID: 22158445
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
